Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. ARTeSYN Biosolutions is projected to generate approximately $30 million in revenue (pro forma) in 2020, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in downstream bioprocessing due to their performance, automation and low hold-up volumes. The proposed acquisition of ARTeSYN, combined with the recent acquisitions of Engineered Molding Technologies (“EMT”) and Non-Metallic Solutions (“NMS”) further establishes Repligen as a premier player in single-use systems and associated integrated flow path assemblies.

Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions

- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -

Repligen to Report Third Quarter 2020 Financial Results

BeiGene

Emergent BioSolutions

Horizon Pharma

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes

WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines. The program has entered stage two, which is focused on both scaling up the manufacturing of this ligand, and on the development and validation of the related affinity chromatography resin. The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines. Repligen anticipates that the final resin product will be commercially available in early 2021.

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines

Repligen: A Niche Play On Biologics

Repligen hasn't seen quite the same tailwind from COVID-19 as some of its larger, more diversified rivals, but pandemic-related product development is still adding about 10% to sales.

Repligen Continues To Gain Share In The Fast-Growing Bioproduction Market

AstraZeneca

Eli Lilly

Dr. Reddy's Labs

Zoetis

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

6 of the Best Pharmaceutical Stocks to Buy Today

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen Corporation (RGEN).

Why Repligen Corporation (RGEN) Could Be an Impressive Growth Stock

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Repligen (RGEN) Down 0.7% Since Last Earnings Report?

The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.

Repligen Reports Record Quarter, Increases 2020 Guidance

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript

Repligen stock broke out Friday after the maker of products and services designed to speed development of coronavirus treatments posted an earnings beat and raised its 2020 outlook.
The post IBD Stock Of The Day Repligen Breaks Out As It Aids In Covid-19 Fight appeared first on Investor's Business Daily.

IBD Stock Of The Day Repligen Breaks Out As It Aids In Covid-19 Fight

Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Q2 Earnings and Revenues Top Estimates

Repligen is building a base and near a possible buy range ahead of its next quarterly earnings report, expected on or around Jul. 30.
The post Coronavirus Play Repligen Near Buy Zone With Earnings Due appeared first on Investor's Business Daily.

Coronavirus Play Repligen Near Buy Zone With Earnings Due

Is  (RGEN) Outperforming Other Medical Stocks This Year?

Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?

Exelixis

EXEL vs. RGEN: Which Stock Is the Better Value Option?

EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?

Webcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT

Repligen to Report Second Quarter 2020 Financial Results

Investors have come to value the company's resilience in an uncertain year.

Here's Why Repligen Rose 33.6% in the First Half of 2020

Ligand Pharmaceuticals

LGND vs. RGEN: Which Stock Is the Better Value Option?

LGND or RGEN: Which Is the Better Value Stock Right Now?

AAON

Cognex

In a low interest rate environment, acquisition targets in growth markets are likely to attract bidders.

These 3 Stocks Are Potential Buyout Targets

Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing

Repligen Announces Agreement to Acquire Engineered Molding Technology

DexCom

JD.com

While many companies were unable to avoid the wrath of the coronavirus pandemic, these three companies stood out as big winners.

3 Great Growth Stocks That Kept Climbing in This Tough Market

WALTHAM, Mass., June  15, 2020  (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role over 23 years of leadership experience across multiple disciplines. She currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare (NYSE:GE). From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue.

Repligen Appoints Carrie Eglinton Manner to Board of Directors

Quest Diagnostics

Fortinet

Okta

Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.

News for Repligen Stock (RGEN)